A large RECOVER Initiative study reports that Paxlovid treatment within five days of infection is associated with reduced Long COVID risk in high-risk adults, while the effect was not seen in low-risk patients. The result reframes where benefit is most apparent for antiviral timing and risk selection in post-acute sequelae prevention.